Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
AMGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$253.30 - $346.85
Previous CloseN/A
Volume614.18K
Average Volume (3M)3.35M
Market Cap
$158.03B
Enterprise Value$190.17B
Total Cash (Recent Filing)$2.27B
Total Debt (Recent Filing)$9.29B
Price to Earnings (P/E)38.9
Beta0.34
Next Earnings
May 01, 2025EPS Estimate
4.28Next Dividend Ex-Date
May 16, 2025Dividend Yield3.09%
Share Statistics
EPS (TTM)7.55
Shares Outstanding537,650,630
10 Day Avg. Volume3,920,089
30 Day Avg. Volume3,348,518
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.08
Price to Cash Flow (P/CF)8.90
P/FCF Ratio7.90
Enterprise Value/Market Cap1.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit9.25
Enterprise Value/Ebitda14.24
Forecast
1Y Price Target
$328.86Price Target Upside16.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
---
Bulls Say, Bears Say
Bulls Say
Clinical DataSuccessful launches and favorable clinical data of biosimilars are expected to drive Amgen's share price.
Financial PerformanceAmgen delivers strong performance with a 19% revenue growth and significant sales increases across multiple products.
Bears Say
Market CompetitionUplizna’s effectiveness compares unfavorably vs. Vyvgart which demonstrated a statistically significant separation as early as week 1.
Patent ExpiryThe patents for key drugs accounting for a significant portion of Amgen's sales are set to expire, leading to potential competition from generics.
Safety ConcernsSafety signals for rocatinlimab include higher rates of pyrexia, chills, headache, and ulcers compared to placebo.
---
Ownership Overview
0.22% Insiders
23.24% Mutual Funds
0.91% Other Institutional Investors
47.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $253.30 and its highest was $346.85 in the past 12 months.
What is Amgen’s market cap?
Amgen’s market cap is $158.03B.
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is May 01, 2025 which is in 14 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on Feb 04, 2025. The company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.091 by $0.219.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.38 which represents an annual dividend yield of 3.09%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is 4.28.
How many shares outstanding does Amgen have?
Amgen has 537,650,630 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $5.31 in its last earnings report, beating expectations of $5.091. Following the earnings report the stock price went up 6.502%.
Which hedge fund is a major shareholder of Amgen?
Currently, no hedge funds are holding shares in AMGN
---
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$328.86 (16.35% Upside)
$328.86 (16.35% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 88%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 969.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $20.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.61%
12-Months-Change
Fundamentals
Return on Equity
67.55%
Trailing 12-Months
Asset Growth
-5.47%
Trailing 12-Months
Company Description
Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
---
AMGN Company Deck
---
AMGN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in 2024 with significant growth in product sales, particularly in oncology and biosimilars. The successful integration of Horizon and robust financial results further reinforce Amgen's position for continued growth. However, challenges such as the upcoming patent expiration for denosumab and expected price declines pose potential risks.Read More>---
AMGN Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
---
AMGN Stock 12 Month Forecast
Average Price Target
$328.86
▲(16.35% Upside)
Technical Analysis
Best Analysts Covering AMGN
1 Year
1 Year Success Rate
24/36 ratings generated profit
1 Year Average Return
+11.31%
reiterated a buy rating 17 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +11.31% per trade.
---